| # | Title | Journal | Year | Citations |
|---|
| 1 | Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies | Lancet Respiratory Medicine,the | 2016 | 433 |
| 2 | Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial | Lancet Respiratory Medicine,the | 2017 | 432 |
| 3 | Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial | Journal of Allergy and Clinical Immunology | 2017 | 376 |
| 4 | Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial | Lancet Infectious Diseases, The | 2013 | 333 |
| 5 | Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study | Clinical Therapeutics | 2016 | 228 |
| 6 | Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma | Journal of Allergy and Clinical Immunology | 2019 | 212 |
| 7 | Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study | Lancet HIV,the | 2015 | 180 |
| 8 | Biomarkers for severe eosinophilic asthma | Journal of Allergy and Clinical Immunology | 2017 | 180 |
| 9 | Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison | Journal of Allergy and Clinical Immunology | 2019 | 175 |
| 10 | Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia | Journal of the American Society of Nephrology: JASN | 2016 | 166 |
| 11 | The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma | Allergy: European Journal of Allergy and Clinical Immunology | 2019 | 106 |
| 12 | Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial | Journal of Allergy and Clinical Immunology | 2020 | 105 |
| 13 | Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis | Journal of Cystic Fibrosis | 2013 | 102 |
| 14 | Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study | Clinical Therapeutics | 2019 | 102 |
| 15 | Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment | Allergy: European Journal of Allergy and Clinical Immunology | 2016 | 93 |
| 16 | Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study | Journal of Asthma | 2018 | 87 |
| 17 | Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis | CKJ: Clinical Kidney Journal | 2019 | 87 |
| 18 | Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial | Annals of Oncology | 2015 | 78 |
| 19 | Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma | Journal of Allergy and Clinical Immunology | 2017 | 78 |
| 20 | Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities | Therapeutic Innovation and Regulatory Science | 2018 | 78 |
| 21 | A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices | Npj Primary Care Respiratory Medicine | 2016 | 75 |
| 22 | Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease | CKJ: Clinical Kidney Journal | 2019 | 63 |
| 23 | Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma | Pediatric Pulmonology | 2019 | 61 |
| 24 | Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma | Journal of Allergy and Clinical Immunology: in Practice | 2018 | 60 |
| 25 | A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus | PLoS ONE | 2016 | 58 |
| 26 | Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants | European Journal of Clinical Pharmacology | 2018 | 52 |
| 27 | Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD | Pulmonary Pharmacology and Therapeutics | 2013 | 47 |
| 28 | Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma | Journal of Allergy and Clinical Immunology | 2015 | 46 |
| 29 | Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison | Respiratory Medicine | 2017 | 46 |
| 30 | Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial | PLoS ONE | 2014 | 45 |
| 31 | Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma | Respiratory Medicine | 2019 | 43 |
| 32 | Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy | Journal of Allergy and Clinical Immunology | 2020 | 42 |
| 33 | Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count | Journal of Allergy and Clinical Immunology | 2022 | 42 |
| 34 | Once‐daily dolutegravir is superior to once‐daily darunavir/ritonavir in treatment‐naïve HIV‐1‐positive individuals: 96 week results from FLAMINGO | Journal of the International AIDS Society | 2014 | 41 |
| 35 | Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis | Respiratory Research | 2019 | 40 |
| 36 | Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils | Pulmonary Pharmacology and Therapeutics | 2014 | 36 |
| 37 | Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA | Respiratory Research | 2019 | 34 |
| 38 | Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial | Diabetes Care | 2020 | 33 |
| 39 | Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma | Allergology International | 2017 | 31 |
| 40 | Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study | International Journal of COPD | 2017 | 31 |
| 41 | Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO | International Journal of COPD | 2021 | 30 |
| 42 | Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility | Respiratory Medicine | 2019 | 28 |
| 43 | Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes | Diabetes, Obesity and Metabolism | 2015 | 26 |
| 44 | An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects | Kidney International Reports | 2018 | 25 |
| 45 | Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma | Allergy, Asthma and Clinical Immunology | 2019 | 25 |
| 46 | Adding new experimental arms to randomised clinical trials: Impact on error rates | Clinical Trials | 2020 | 25 |
| 47 | Usability of mepolizumab single-use prefilled syringe for patient self-administration | Journal of Asthma | 2020 | 23 |
| 48 | Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes | Diabetes, Obesity and Metabolism | 2015 | 22 |
| 49 | Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life | Advances in Therapy | 2018 | 22 |
| 50 | Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions | Respiratory Research | 2021 | 22 |
